A3: Adaptation of tumor cells to changes in the lung microenvironment through p53 mutations (Prof. Stiewe, Dr. PD Wanzel)
Subproject A3 studies the significance of p53 mutations (which are the most frequent gene mutations in lung carcinomas) for the adaptation of tumor cells to hypoxia, reactive oxygen intermediates, inflammatory cytokines and metabolic changes that occur as a result of tumor growth, therapies or concomitant diseases. CRISPR-based high-throughput mutagenesis of the p53 gene will characterize p53 mutations with regard to their individual oncogenic potential in order to support personalized therapy decisions.